Pharmacological management of breathlessness in COPD: recent advances and hopes for the future

References

• Buist AS, McBurnie MA, Vollmer WM, et al.; on behalf of the BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–750.
   PubMed Web of Science ®Google Scholar
• Raghavan N, Lam Y-M, Webb KA, et al. Components of the COPD Assessment Test (CAT) associated with a diagnosis of COPD in a random population sample. COPD. 2012;9(2):175–183.
   PubMedGoogle Scholar
• Casanova C, Cote C, De Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(6):591–597.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Donati P, Nicosia F, et al. Inspiratory capacity predicts mortality in patients with chronic obstructive pulmonary disease. Respir Med. 2008;102(4):613–619.
   PubMed Web of Science ®Google Scholar
• Celli BR, Decramer M, Lystig T, et al. Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respir Res. 2012;13:66.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Izumi T, Tsukino M, et al.; on behalf of the Kansai COPD Registry and Research Group in Japan. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434–1440.
   PubMed Web of Science ®Google Scholar
• Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331–342.
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med. 2003;167:544–549.
   PubMed Web of Science ®Google Scholar
• Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004;23:28–33.
   PubMed Web of Science ®Google Scholar
• Parshall MB, Schwartzstein RM, Adams L; the ATS Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–452.
   PubMed Web of Science ®Google Scholar
• Chonan T, Mulholland MB, Cherniack NS, et al. Effects of voluntary constraining of thoracic displacement during hypercapnia. J Appl Physiol. 1987;63:1822–1828.
   PubMed Web of Science ®Google Scholar
• El-Manshawi A, Killian KJ, Summers E, et al. Breathlessness during exercise with and without resistive loading. J Appl Physiol. 1986;61:896–905.
   PubMed Web of Science ®Google Scholar
• Killian KJ, Jones NL. Respiratory muscles and dyspnea. Clin Chest Med. 1988;9:237–248.
   PubMed Web of Science ®Google Scholar
• Killian KJ, Gandevia SC, Summers E, et al. Effect of increased lung volume on perception of breathlessness, effort and tension. J Appl Physiol. 1984;57:686–691.
   PubMed Web of Science ®Google Scholar
• Campbell EJM, Gandevia SC, Killian KJ, et al. Changes in the perception of inspiratory resistive loads during partial curarization. J Physiol. 1990;309:93–100.
   Google Scholar
• Altose M, Cherniack N, Fishman AP. Respiratory sensations and dyspnea. J Appl Physiol. 1985;58:1051–1054.
   PubMed Web of Science ®Google Scholar
• Mahler DA, O’Donnell DE. Recent advances in dyspnea. Chest. 2015;147(1):232–241.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thor Soc. 2007;4:145–168.
   PubMedGoogle Scholar
• O’Donnell DE, Ora J, Webb KA, et al. Mechanisms of activity-related dyspnea in pulmonary diseases. Respir Physiol Neurobiol. 2009;167(1):116–132.
   PubMed Web of Science ®Google Scholar
• Jones NL. The ins and outs of breathing: how we learnt about the body’s most vital function. Bloomington: iUniverse; 2011.
   Google Scholar
• Gandevia B, Hugh-Jones P. Terminology for measurements of ventilatory capacity; a report to the thoracic society. Thorax. 1957;12(4):290–293.
   PubMedGoogle Scholar
• Leblanc P, Bowie DM, Summers E, et al. Breathlessness and exercise in patients with cardiorespiratory disease. Am Rev Respir Dis. 1986;133:21–25.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Guenette JA, Maltais F, et al. Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. Chest. 2012;141:753–762.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:770–777.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:1557–1565.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis. 1993;148:1351–1357.
   PubMed Web of Science ®Google Scholar
• Jolley CJ, Luo YM, Steier J, et al. Neural respiratory drive and breathlessness in COPD. Eur Respir J. 2015;45(2):355–364.
   PubMed Web of Science ®Google Scholar
• Guenette JA, Chin RC, Cheng S, et al. Mechanisms of exercise intolerance in global initiative for chronic obstructive lung disease grade 1 COPD. Eur Respir J. 2014;44:1177–1187.
   PubMed Web of Science ®Google Scholar
• Faisal A, Alghamdi BJ, Ciavaglia CE, et al. Common neurophysiological mechanisms of dyspnea in chronic interstitial and obstructive lung disorders. Am J Respir Crit Care Med. 2016;193(3):299–309.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol. 2006;101:1025–1035.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med. 1997;155:109–115.
   PubMed Web of Science ®Google Scholar
• Laveneziana P, Webb KA, Ora J, et al. Evolution of dyspnea during exercise in COPD: impact of critical volume constraints. Am J Respir Crit Care Med. 2011;184(12):1367–1373.
   PubMed Web of Science ®Google Scholar
• Chen Z, Eldridge FL, Wagner PG. Respiratory-associated thalamic activity is related to level of respiratory drive. Respir Physiol. 1992;90:99–113.
   PubMedGoogle Scholar
• Chen Z, Eldridge FL. Inputs from upper airway affect firing of respiratory associated midbrain neurons. J Appl Physiol. 1997;83:196–203.
   PubMed Web of Science ®Google Scholar
• Eldridge F, Chen Z. Respiratory-associated rhythmic firing of midbrain neurons is modulated by vagal input. Respir Physiol. 1992;90:31–46.
   PubMedGoogle Scholar
• Guz A, Noble MIM, Eisele JH, et al. Experimental results of vagal block in cardiopulmonary disease. In: Porter R, ed. Breathing: Hering-Breuer centenary symposium. London: Churchill; 1970. p. 315.
   Google Scholar
• Banzett RB, Lansing RW, Reid MB, et al. ‘Air hunger’ arising from increased PCO2 in mechanically ventilated quadriplegics. Respir Physiol. 1989;76:53–67.
   PubMedGoogle Scholar
• Banzett RB, Lansing RW, Brown R, et al. ‘Air hunger’ from increased PCO2 persists after complete neuromuscular block in humans. Respir Physiol. 1990;81:1–17.
   PubMedGoogle Scholar
• Banzett RB, Mulnier HE, Murphy K, et al. Breathlessness in humans activates insular cortex. Neuroreport. 2000;11:2117–2120.
   PubMed Web of Science ®Google Scholar
• Gandevia SC, Macefield G. Projection of low-threshold afferents from human intercostal muscles to the cerebral cortex. Respir Physiol. 1989;77:203–214.
   PubMedGoogle Scholar
• Gandevia SC, Killian K, McKenzie DK, et al. Respiratory sensations, cardiovascular control, kinaesthesia and transcranial stimulation during paralysis in humans. J Physiol. 1993;470:85–107.
   PubMed Web of Science ®Google Scholar
• Gagnon P, Bussières JS, Ribeiro F, et al. Influences of spinal anesthesia on exercise tolerance in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(7):606–615.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Hong HH, Webb KA. Effects of chest wall restriction and deadspace loading on dyspnea and exercise tolerance in healthy normals. J Appl Physiol. 2000;88:1859–1869.
   PubMed Web of Science ®Google Scholar
• Manning HL, Shea SA, Schwartzstein RM, et al. Reduced tidal volume increases ’air hunger’ at fixed PCO2 in ventilated quadriplegics. Respir Physiol. 1992;90:19–30.
   PubMedGoogle Scholar
• Opie L, Smith A, Spalding J. Conscious appreciation of the effects produced by independent changes of ventilation volume and of end-tidal PCO2 in paralysed patients. J Physiol. 1959;149:494–499.
   PubMed Web of Science ®Google Scholar
• Schwartzstein RM, Simon PM, Weiss JW, et al. Breathlessness induced by dissociation between ventilation and chemical drive. Am Rev Respir Dis. 1989;139:1231–1237.
   PubMed Web of Science ®Google Scholar
• Wadell K, Webb KA, Preston ME, et al. Impact of pulmonary rehabilitation on the major dimensions of dyspnea in COPD. COPD. 2013;10(4):425–435.
   PubMedGoogle Scholar
• Von Leupoldt A, Dahme B. Cortical substrates for the perception of dyspnea. Chest. 2005;128:345–354.
   PubMed Web of Science ®Google Scholar
• Von Leupoldt A, Sommer T, Kegat S, et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med. 2008;177:1026–1032.
   PubMed Web of Science ®Google Scholar
• Evans KC, Banzett RB, Adams L, et al. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol. 2002;88:1500–1511.
   PubMed Web of Science ®Google Scholar
• Pattinson K. Basic science for the chest physician: functional brain imaging in respiratory medicine. Thorax. 2015;70(6):598–600.
   PubMed Web of Science ®Google Scholar
• Langer D, Ciavaglia CE, Neder JA, et al. Lung hyperinflation in COPD: mechanisms, clinical implications and treatment. Expert Rev Respir Dis. 2014;8(6):731–749.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with “irreversible” emphysema. Eur Respir J. 2001;18:914–920.
   PubMed Web of Science ®Google Scholar
• Newton MF, O’Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest. 2002;121:1042–1050.
   PubMed Web of Science ®Google Scholar
• Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743–1748.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832–840.
   PubMed Web of Science ®Google Scholar
• Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128:1168–1178.
   PubMed Web of Science ®Google Scholar
• Deesomchok A, Webb KA, Forkert L, et al. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD. 2010;7:428–437.
   PubMedGoogle Scholar
• O’Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in COPD. Eur Respir J. 2004;24:86–94.
   PubMed Web of Science ®Google Scholar
• Peters MM, Webb KA, O’Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on dyspnea and exercise performance in normoxic COPD. Thorax. 2006;61:559–567.
   PubMed Web of Science ®Google Scholar
• Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011;105:580–587.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Casaburi R, Vincken W, et al.; on behalf of the INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105:1030–1036.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:542–549.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130:647–656.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Duguet A, Similowski T, et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J. 1998;12:799–804.
   PubMed Web of Science ®Google Scholar
• Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:967–975.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957–965.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(5):1087–1092.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108:584–592.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Wagner F, Khindri S, et al. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD. 2011;8:340–345.
   PubMedGoogle Scholar
• Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J COPD. 2012;7:503–513.
   Google Scholar
• Man WD, Mustfa N, Nikoletou D, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004;59:471–476.
   PubMed Web of Science ®Google Scholar
• Neder JA, Fuld JP, Overend T, et al. Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respir Med. 2007;101:2056–2064.
   PubMed Web of Science ®Google Scholar
• Worth H, Förster K, Eriksson G, et al. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med. 2010;104:1450–1459.
   PubMed Web of Science ®Google Scholar
• Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122(1):47–55.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(8):1084–1091.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124(3):834–843.
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399–404.
   PubMed Web of Science ®Google Scholar
• Kornman O, Dahl R, Centanni S, et al.; on behalf of the INLIGHT-2 study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273–279.
   PubMed Web of Science ®Google Scholar
• Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J. 2002;19(5):936–943.
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R, et al.; on behalf of the INVOLVE Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–479.
   PubMed Web of Science ®Google Scholar
• Gotfried MH, Kerwin EM, Lawrence D, et al. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. COPD. 2012;9(6):629–636.
   PubMedGoogle Scholar
• Kinoshita M, Lee SH, Hang L-W, et al. Indacaterol Asian COPD Study Investigators. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology. 2012;17(2):379–389.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Fogarty C, Lötvall J, et al.; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155–162.
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217–224.
   PubMed Web of Science ®Google Scholar
• Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration. 2006;73(4):420–427.
   PubMed Web of Science ®Google Scholar
• Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106–1114.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D’Urzo AD, Gelb AF, et al.; ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9(2):90–101.
   PubMedGoogle Scholar
• Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40(4):830–836.
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.
   PubMed Web of Science ®Google Scholar
• Mahler D, Mahler DA, Decramer M, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43(6):1599–1609.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546.
   PubMed Web of Science ®Google Scholar
• Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991.
   PubMed Web of Science ®Google Scholar
• Puente-Maestu L, Villar F, de Miguel J, et al. Clinical relevance of constant power exercise duration changes in COPD. Eur Respir J. 2009;34:340–345.
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al.; on behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416–469.
   PubMed Web of Science ®Google Scholar
• Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J. 2016;47(2):429–460.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43(6):1599–1609.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Witek TJ. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2:99–103.
   PubMedGoogle Scholar
• Elkington H, White P, Addington-Hall J, et al. The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. Palliat Med. 2005;19(6):485–491.
   PubMed Web of Science ®Google Scholar
• Jones PW, Brusselle G, Dal Negro RW, et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011;105:57–66.
   PubMed Web of Science ®Google Scholar
• Hughes J, Kosterlitz HW. Opioid Peptides: introduction. Br Med Bull. 1983;39:1–3.
   PubMed Web of Science ®Google Scholar
• Feng Y, He X, Yang Y, et al. Current research on opioid receptor function. Curr Drug Targets. 2012;13:230–246.
   PubMed Web of Science ®Google Scholar
• Krajnik M, Jassem E, Sobanski P. Opioid receptor bronchial tree: current science. Curr Opin Support Palliat Care. 2014;8:191–199.
   PubMed Web of Science ®Google Scholar
• Schlaepfer TE, Strain EC, Greenberg BD, et al. Site of opioid action in the human brain: mu and kappa agonists’ subjective and cerebral blood flow effects. Am J Psychiatry. 1998;155:470–473.
   PubMed Web of Science ®Google Scholar
• Petrovic P, Kalso E, Petersson KM, et al. Placebo and opioid analgesia – imaging a shared neuronal network. Science. 2002;295(5560):1737–1740.
   PubMed Web of Science ®Google Scholar
• Leppä M, Korvenoja A, Carlson S, et al. Acute opioid effects on human brain as revealed by functional magnetic resonance imaging. Neuroimage. 2006;31:661–669.
   PubMed Web of Science ®Google Scholar
• Mahler DA. Opioids for refractory dyspnea. Expert Rev Respir Med. 2013;7(2):123–134.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Gifford AH, Waterman LA, et al. Effect of increased blood levels of β-endorphin on perception of breathlessness. Chest. 2013;143:1378–1385.
   PubMed Web of Science ®Google Scholar
• Boyden JY, Connor SR, Otolorin L, et al. Nebulized medications for the treatment of dyspnea: a literature review. J Aerosol Med Pulm Drug Deliv. 2015;28(1):1–19.
   PubMed Web of Science ®Google Scholar
• Woodcock AA, Gross ER, Gellert A, et al. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med. 1981;305:1611–1616.
   PubMed Web of Science ®Google Scholar
• Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breathlessness in “pink puffers”. Br Med J (Clin Res Ed). 1983;286:675–677.
   PubMed Web of Science ®Google Scholar
• Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57:939–944.
   PubMed Web of Science ®Google Scholar
• Ekström M, Nilsson F, Abernethy AA, et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc. 2015;12:1079–1092.
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Bland JM, Oxberry SG, et al. Clinically important differences in the intensity of chronic refractory breathlessness. J Pain Symptom Manage. 2013;46:957–963.
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Bland JM, Oxberry SG, et al. Opioids for chronic refractory breathlessness: patient predictors of beneficial response. Eur Respir J. 2013;42:758–766.
   PubMed Web of Science ®Google Scholar
• Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. Bmj. 2003;327:523–528.
   PubMed Web of Science ®Google Scholar
• Dudgeon D. Management of dyspnea at the end of life. In: Mahler DA, O’Donnell DE, eds. Dyspnea. New York: Taylor & Francis; 2005. p. 429–461.
   Google Scholar
• Lanken PN, Terry PB, Delisser HM, et al.; ATS End-of-Life Care Task Force. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177(8):912–927.
   PubMed Web of Science ®Google Scholar
• Rocker G, Horton R, Currow D, et al. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax. 2009;64:910–915.
   PubMed Web of Science ®Google Scholar
• Booth S, Bausewein C, Higginson I, et al. Pharmacological treatment of refractory breathlessness. Expert Rev Respir Med. 2009;3:21–36.
   PubMedGoogle Scholar
• Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011;42:388–399.
   PubMed Web of Science ®Google Scholar
• Smallwood N, Le B, Currow D, et al. Management of refractory breathlessness with morphine in patients with chronic obstructive pulmonary disease. Intern Med J. 2015;45:898–904.
   PubMed Web of Science ®Google Scholar
• Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Br J Clin Pharmacol. 2016;81(1):161–170.
   PubMed Web of Science ®Google Scholar
• Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000;66:2221–2231.
   PubMed Web of Science ®Google Scholar
• Bausewein C, Simon ST. Inhaled nebulized and intranasal opioids for the relief of breathlessness. Curr Opin Support Palliat Care. 2014;8:208–212.
   PubMed Web of Science ®Google Scholar
• Currow DC, Ekstrom M, Abernethy AP. Opioids for chronic refractory breathlessness: right patient, right route? Drugs. 2014;74:1–6.
   PubMed Web of Science ®Google Scholar
• Jensen D, Alsuhail A, Viola R, et al. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Eur Respir J. 2013;42:758–766.
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Mulley BA, Peake MD. Dose reponse to oral theophylline in severe chronic obstructive airways d isease. BMJ. 1988;297(6662):1506–1510.
   PubMed Web of Science ®Google Scholar
• Dreyse J, Silva F, Diaz O, et al. Clinical and functional benefits of adding theophylline to a standard treatment with short acting bronchodilators in patients with COPD. Revista Medica De Chile. 2005;133(10):1211–1219.
   PubMed Web of Science ®Google Scholar
• Waterhouse JC, Pritchard SM, Howard P. Hyperinflation, trapped gas and theophylline in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis. 1993;48(2):126–129.
   PubMedGoogle Scholar
• Murciano D, Aubier M, Lecocguic Y, et al. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med. 1984;311(6):349–353.
   PubMed Web of Science ®Google Scholar
• Murciano D, Auclair MH, Pariente R, et al. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med. 1989;320(23):1521–1525.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Bredenbröker D, Brose M, et al. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J. 2012;39:1104–1112.
   PubMed Web of Science ®Google Scholar
• Tse HN, Raiteri L, Wong KY, et al. High-dose N-?acetylcysteine in stable chronic obstructive pulmonary disease: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144(1):106–118.
   PubMed Web of Science ®Google Scholar
• Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-?acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552–1560.
   PubMed Web of Science ®Google Scholar
• Stav D, Raz M. Effect of N-?acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest. 2009;136(2):381–386.
   PubMed Web of Science ®Google Scholar
• Maurer J, Rebbapragada V, Borson S, et al.; ACCP Workshop Panel on Anxiety and Depression in COPD. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4 Suppl):43S–56S.
   PubMed Web of Science ®Google Scholar
• Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31(1):58–69.
   PubMed Web of Science ®Google Scholar
• Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2010 Jan;20(1):CD007354.
   Google Scholar
• Hardy J, Randall C, Pinkerton E, et al. A randomised, double-blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life-limiting disease. Support Care Cancer. 2016. published online 2016 Feb 18. doi:10.1007/s00520-016-3125-2.
   Google Scholar
• Navigante AH, Castro MA, Cerchietti LC. Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage. 2010;39(5):820–830.
   PubMed Web of Science ®Google Scholar
• Allcroft P, Margitanovic V, Greene A, et al. The role of benzodiazepines in breathlessness: A single site, open label pilot of sustained release morphine together with clonazepam. J Palliative Med. 2013;16(7):741–744.
   PubMed Web of Science ®Google Scholar
• Yohannes AM, Müllerová H, Hanania N, et al. Long-term course of depression trajectories in patients with COPD: A three year follow-up analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort. Chest. 2016;149:916–926.
   PubMed Web of Science ®Google Scholar
• Yohannes AM, Alexopoulos GS. Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes. Drugs Aging. 2014;31:483–492.
   PubMed Web of Science ®Google Scholar
• Owens D. Nebulized furosemide for the treatment of dyspnea. J Hosp Palliat Nurs. 1999;16:418–422.
   Google Scholar
• Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care. 2007;52:900–910.
   PubMed Web of Science ®Google Scholar
• Newton PJ, Davidson PM, Macdonald P, et al. Nebulized furosemide for the management of dyspnea: does the evidence support its use? J Pain Symptom Manage. 2008;36:424–441.
   PubMed Web of Science ®Google Scholar
• Ong K-C, Kor A-C, Chong W-F, et al. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1028–1033.
   PubMed Web of Science ®Google Scholar
• Jensen D, Amjadi K, Harris-McAllister V, et al. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax. 2008;63:606–613.
   PubMed Web of Science ®Google Scholar
• Sheikh Motahar Vahedi H, Mahshidfar B, Rabiee H, et al. The adjunctive effect of nebulized furosemide in COPD exacerbation: a randomized controlled clinical trial. Respir Care. 2013;58:1873–1877.
   PubMed Web of Science ®Google Scholar
• Awan S, Wilcock A. Nonopioid medication for the relief of refractory breathlessness. Curr Opin Support Palliat Care. 2015;9:227–231.
   PubMed Web of Science ®Google Scholar
• Moosavi SH, Binks AP, Lansing RW, et al. Effect of inhaled furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol. 2007;156:1–8.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–1276.
   PubMedGoogle Scholar
• O’Donnell DE, Hernandez P, Kaplan A, et al.; on behalf of the Canadian Thoracic Society. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can Respir J. 2008;15(Suppl A):1A–8A.
   PubMed Web of Science ®Google Scholar
• Marciniuk DD, Goodridge D, Hernandez P, et al.; Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18(2):69–78.
   PubMed Web of Science ®Google Scholar